Comparative Study of the Tomey OA-2000, Tomey CASIA2, and the LenStar LS900

September 26, 2023 updated by: Tomey Corporation

This is a prospective comparative study that will be conducted at one clinical site in the United States, in which subjects who sign an informed consent form and fulfil all inclusion and exclusion criteria, will have OCT scans obtained using the test and the predicate devices.

There will be two main types of analyses performed as part of this study, including 1) a precision analysis, and 2) an agreement analysis.

The precision analyses will be conducted utilizing all complete complements of acceptable scans from the test devices and predicate device for each of the 3 configurations. A complete complement of acceptable scans can be defined as subjects having 3 acceptable replicate scans on each of the 3 devices, at each of the 3 configurations. This is also synonymous with 3 scans for each of the 3 configurations on all 3 devices. If subjects have more than 3 acceptable scans per configuration on a device, only the first 3 will be considered for analyses.

The agreement analysis will be conducted utilizing the first set of acceptable scans from each instrument for all overlapping measurement types (for all measurement types two or more of the devices have in common) related to performance endpoints.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

167

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Massachusetts
      • Woburn, Massachusetts, United States, 01801
        • Recruiting
        • NorthEast Eye Research Associates
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Normal subjects (22 years of age or older) Cataract subjects (22 years of age or older), Special eyes subjects (22 years of age or older)

Description

Inclusion Criteria - Normal Cohort:

  1. Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
  2. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
  3. Subjects who agree to participate in the study.

Inclusion Criteria - Cataract Cohort:

  1. Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
  2. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
  3. Subjects who agree to participate in the study;
  4. Subjects diagnosed with cataract classified per the LOCS III scale.

Inclusion Criteria - Special Eyes Cohort (eyes without a natural lens or eyes containing artificial materials):

  1. Male or female subjects 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed;
  2. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date;
  3. Subjects who agree to participate in the study;
  4. Subjects diagnosed with one or both eyes having aphakia, pseudophakia or silicone oil.

Exclusion Criteria - Normal Cohort:

  1. Subjects unable to tolerate ophthalmic imaging;
  2. Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
  3. Subjects with any current ocular pathology, as determined by self-report and confirmed by the investigator assessment and/or confirmed by the investigator assessment at the study visit;
  4. Subjects that present with an active ocular infection in either eye;
  5. Subjects who have a history of ocular surgery, including laser therapy/surgery;
  6. Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Exclusion Criteria - Cataract Cohort:

  1. Subjects unable to tolerate ophthalmic imaging;
  2. Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
  3. Subjects with corneal or conjunctival abnormalities that may affect adequate assessment of the anterior chamber in either eye;
  4. Subjects that present with an active ocular infection in either eye;
  5. Subjects who have a history of ocular surgery, including laser therapy/surgery;
  6. Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Exclusion Criteria - Special Eyes Cohort (eyes without a natural lens or eyes containing artificial materials):

  1. Subjects unable to tolerate ophthalmic imaging;
  2. Subjects who did not take off their contact lenses earlier than 15 minutes prior to the study;
  3. Subjects with corneal or conjunctival abnormalities that may affect adequate assessment of the anterior chamber in either eye;
  4. Subjects that present with an active ocular infection in either eye;
  5. Subjects with a condition or in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
  6. Subjects with evidence of silicone oil emulsification;
  7. Subjects with silicone oil in the anterior chamber;
  8. Subjects with adherence of oil droplets to an intraocular lens.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Normal
Optical measurements by optical biometers and an OCT
Cataract
Optical measurements by optical biometers and an OCT
Special eye
Optical measurements by optical biometers and an OCT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Agreement between the test devices and predicate device
Time Frame: Through study completion, approximately 4 months
Agreement between each of the test devices and the predicate device will be evaluated by the mean difference and SD, the 95% limits of agreement (LOA), the Bland-Altman plots, and Deming regression for each subject population.
Through study completion, approximately 4 months
Precision of the test devices
Time Frame: Through study completion, approximately 4 months
A crossed two-way random-effects analysis of variance (ANOVA) model will be used to estimate the repeatability and reproducibility limits of each scan parameter by subject population and study device (test and predicate device). This ANOVA model will include the configuration, subject, and interaction between configuration and subject as the factors. Repeatability and reproducibility standard deviations, as well as the corresponding coefficient of variations (CVs), will be calculated using this ANOVA model.
Through study completion, approximately 4 months
Safety of the test devices
Time Frame: Through study completion, approximately 4 months
Adverse events reported will be listed by subject.
Through study completion, approximately 4 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ioanis Panagiotopoulos, Dr., NorthEast Eye Research Associates

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 23, 2023

Primary Completion (Estimated)

October 31, 2023

Study Completion (Estimated)

October 31, 2023

Study Registration Dates

First Submitted

September 12, 2023

First Submitted That Met QC Criteria

September 26, 2023

First Posted (Actual)

October 3, 2023

Study Record Updates

Last Update Posted (Actual)

October 3, 2023

Last Update Submitted That Met QC Criteria

September 26, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Tomey OA-2000-001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cataract

Clinical Trials on Optical measurement

3
Subscribe